CN113975363A - 一种增强免疫力的粉雏菊组合物 - Google Patents
一种增强免疫力的粉雏菊组合物 Download PDFInfo
- Publication number
- CN113975363A CN113975363A CN202111156452.5A CN202111156452A CN113975363A CN 113975363 A CN113975363 A CN 113975363A CN 202111156452 A CN202111156452 A CN 202111156452A CN 113975363 A CN113975363 A CN 113975363A
- Authority
- CN
- China
- Prior art keywords
- composition
- daisy
- pink
- immunity
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000005633 Chrysanthemum balsamita Nutrition 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000036039 immunity Effects 0.000 title claims abstract description 26
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 22
- 241000723353 Chrysanthemum Species 0.000 title 1
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 11
- 235000008397 ginger Nutrition 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 244000260524 Chrysanthemum balsamita Species 0.000 claims abstract 12
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 10
- 241000234314 Zingiber Species 0.000 claims description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 10
- 235000011477 liquorice Nutrition 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 15
- 230000035755 proliferation Effects 0.000 abstract description 9
- 210000000265 leukocyte Anatomy 0.000 abstract description 7
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 6
- 230000028327 secretion Effects 0.000 abstract description 6
- 102100037850 Interferon gamma Human genes 0.000 abstract description 5
- 108010074328 Interferon-gamma Proteins 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 4
- 235000013402 health food Nutrition 0.000 abstract description 2
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 235000013376 functional food Nutrition 0.000 abstract 1
- 230000000091 immunopotentiator Effects 0.000 abstract 1
- 241000132023 Bellis perennis Species 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 9
- 239000013641 positive control Substances 0.000 description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000452953 Bernardia myricifolia Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002884 effect on inflammation Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供的粉雏菊组合物本方中，是属于纯天然的保健食品。由粉雏菊、生姜、甘草，上述三种纯天然食品相辅相成，经过煮沸、过滤、蒸馏，从而具有增强免疫力的作用。实验表明，本发明粉雏菊组合物能够增加白细胞数，提高淋巴细胞的增殖，以及淋巴细胞因子IFN‑γ和IL‑6的分泌，从而起到增强免疫力的作用。本文首次研究了粉雏菊组合物增强免疫力的作用，为进一步发展天然功能性食品并可作为免疫增强剂在临床上发挥其增强免疫作用提供了基础。
Description
技术领域
本发明研制出一种增强免疫力的保健食品，属于食品保健技术领域。
背景技术
体液免疫机制在抵御病原体时起到了至关重要的作用，也是大多数疫苗免疫成功的基本保护机制。淋巴细胞的分裂增殖是淋巴细胞活化的主要表现，同时也是体液免疫的重要组成部分。淋巴细胞通过血液循环等方式连接机体各处的免疫组织与器官，构建起体液免疫机制。
细胞因子是一种多功能的多效蛋白，在细胞间的通信和细胞激活中起着至关重要的作用，通常由免疫系统细胞激活产生，在免疫反应的发展和控制中发挥关键作用。IFN-γ是辅助Th1细胞的标志性的细胞因子，具有抗病毒、免疫调节及抗肿瘤特性，通过上调转录因子T-bet而促进辅助Th1细胞的分化。IL-6是活化的Th2细胞合成纤维细胞产生的淋巴因子，在人体代谢、自身免疫、细胞分化、疾病治疗等方面都具有重要作用，能够促进T细胞群体扩增和活化以及B细胞分化。
粉雏菊泡水喝具有清热解毒、清肝明目，以及滑肠通便的作用。粉雏菊中含有大量的挥发油和氨基酸成分，其中含量最高的是黄酮物质，能够起到清热解毒作用，对炎症问题有不错的治疗效果。除此之外，粉雏菊还可以帮助人体解毒，可以发挥出清肝明目的效果，对于眼部健康很有好处。如果患上风热感冒的情况，粉雏菊也有很好的治疗作用。粉雏菊泡水还可以加速人体的新陈代谢，让我们保持肠道的通畅，有效避免便秘的发生。除此之外，粉雏菊还有提高人体免疫力、预防感冒的作用，而且对部分人还有美白的效果。
生姜具有解表散寒、温中止呕、温肺止咳、解毒的功效，常用于风寒感冒，脾胃寒症，胃寒呕吐，肺寒咳嗽，解鱼蟹毒。生姜还可以促进人体的血液循环，用来解酒，治疗因肌肉引起的腰、肩肌肉疼痛。
甘草具有补脾益气，清热解毒，祛痰止咳，缓急止痛，调和诸药之功效。常用于脾胃虚弱，倦怠乏力，心悸气短，咳嗽痰多，脘腹、四肢挛急疼痛，痈肿疮毒，缓解药物毒性。
本研究选取了三位药食同源的纯天然食品，研制出一种增强免疫力的粉雏菊组合物，其不良反应少，药效稳定，适宜长期服用。
发明内容
本发明的目的是研制出一种增强免疫力的粉雏菊组合物。
本发明的目的是通过以下技术方案实现的：
一种增强免疫力的粉雏菊组合物，由粉雏菊、生姜、甘草三种中药原料制成。
进一步地限定，下述重量份数配比制成，包括以下组分：粉雏菊20-50重量份、生姜5-30重量份、甘草5-25重量份。
进一步地限定，所述组分进行优选：粉雏菊20-35重量份、生姜5-20重量份、甘草5-15重量份。
进一步地限定，将原料总重量10倍份的蒸馏水，浸泡半小时，然后煎煮2次，每次煎煮1.5小时，合并煎液，尽快过滤，除去滤渣，将滤液浓缩至适当体积，制得一种增强免疫力的粉雏菊组合物。
进一步地限定，所述增强免疫力的粉雏菊组合物的剂型可以为煎剂口服液、颗粒剂或胶囊剂。
上述中天然食品均可以通过商业途径购买得到。
本发明的有益效果为：一种增强免疫力的粉雏菊组合物，是机体免疫系统良好的增强剂，从细胞免疫、体液免疫等多方面来增强免疫力，并且具有服用剂量小、吸收较快、质量稳定、携带和服用方便、易保存等优点。
附图说明
图1是一种增强免疫力的粉雏菊组合物的效果图，增加白细胞数，提高淋巴细胞的增殖，提高淋巴细胞IFN-γ和IL-6的分泌。
具体实施方式
为了使本领域人员更好的理解该技术方案并予以实施，下面结合具体例子对本发明进行进一步说明。
一种增强免疫力的粉雏菊组合物，所述组分由下述重量份数配比制成：粉雏菊20-35重量份、生姜5-20 重量份、甘草5-15重量份。将原料总重量10倍份的蒸馏水，浸泡半小时，然后煎煮2次，每次煎煮1.5 小时，合并煎液，尽快过滤，除去滤渣，将滤液浓缩至适当体积，制得一种增强免疫力的粉雏菊组合物。
实用例1
一种增强免疫力的粉雏菊组合物，所述组分由下述重量份数配比制成：粉雏菊22重量份、生姜8重量份、甘草7重量份。按照上述方法制备粉雏菊组合物。
实用例2
一种增强免疫力的粉雏菊组合物，所述组分由下述重量份数配比制成：粉雏菊27重量份、生姜11重量份、甘草10重量份。按照上述方法制备粉雏菊组合物。
实用例3
一种增强免疫力的粉雏菊组合物，所述组分由下述重量份数配比制成：粉雏菊32重量份、生姜14重量份、甘草13重量份。按照上述方法制备粉雏菊组合物。
本发明研制的粉雏菊组合物对免疫力的影响参见以下实验：
一、实验方法：
1.实验动物及分组
Balb/c小鼠SPF级，体重(20±2)g，6-8周龄，锦州医科大学生命科学院，生产许可证号SCXK (辽)2014-0004。
将小鼠随机分为6组，每组10只，分别为空白对照组，模型组，阳性对照组，实例1组，实例2组，实例3组。除空白对照组外，其余各组仅于7-9天注射环磷酰胺(100mg/kg·bw)，建立免疫抑制模型。阳性对照组采用左旋咪唑(40mg/kg·bw)灌胃，持续14天。实例1、2、3组小鼠采用不同剂量的粉雏菊组合物(100mg/kg·bw)灌胃，持续14天。
2.血液指标
将小鼠的眼球摘除，立即取血加入抗凝管。采用血液分析仪对白细胞。
3.淋巴细胞的制备
将各组脾脏分离放入无菌超干净工作台，放入PBS中剪碎，用200目细胞筛网过滤，加入红细胞裂解液裂解红细胞，然后在含有胎牛血清的RPMI-1640培养基中培养，经台盼蓝检测使细胞活力达95％以上，并将细胞密度调节至5×106个/mL，得到小鼠淋巴细胞悬浮液用于后续研究。
4.淋巴细胞的增殖
使用96孔细胞培养板，每孔中加入100μL淋巴细胞悬浮液，37℃5％CO2培养48h，每孔加入 20μL MTT液，继续培养4h，弃去上清液，加入150μL DMSO，用酶标仪在570nm下测定OD值。
5.淋巴细胞因子的分泌
使用24孔细胞培养板，每孔中加入1mL淋巴细胞悬浮液，37℃5％CO2培养48h，具体操作参考小鼠IFN-γ、IL-6试剂盒说明书进行。
二、实验结果：
1.粉雏菊组合物对血液指标的影响
如表1所示，与空白对照组相比，模型组白细胞显著降低(P<0.01),说明环磷酰胺显著降低了白细胞的数量。与模型组相比，阳性对照组和实例1、2、3组小鼠的白细胞数量显著升高(P<0.01)。结果表明，本实验小鼠免疫抑制模型造模成功，粉雏菊组合物可有效提高小鼠白细胞数量(P<0.01)，表明粉雏菊组合物能够增强免疫抑制小鼠的免疫力。
表1.粉雏菊组合物对血液指标的影响
| 组别 | 白细胞(×10<sup>9</sup>/L) |
| 空白对照组 | 5.64±0.07 |
| 模型组 | 3.82±0.09** |
| 阳性对照组 | 5.34±0.07**## |
| 实例1组 | 4.52±0.09**## |
| 实例2组 | 4.87±0.09**## |
| 实例3组 | 4.88±0.06**## |
注：表1中，与正常对照组比较，*P<0.05,**P<0.01；与模型组比较，#P<0.05,##P<0.01。
2.粉雏菊组合物对淋巴细胞增殖的影响
如表2所示，与空白对照组相比，模型组淋巴细胞的增殖指数显著降低(P<0.05)，说明环磷酰胺显著降低了细胞免疫。与模型组相比，阳性对照组和实例1、2、3组小鼠的淋巴细胞增殖有显著促进作用(P <0.05)。结果表明，粉雏菊组合物可以通过促进小鼠淋巴细胞的增殖反应来增强小鼠的细胞免疫反应。
表2.粉雏菊组合物对淋巴细胞增殖的影响
| 组别 | OD值 |
| 空白对照组 | 1.69±0.02 |
| 模型组 | 1.05±0.03** |
| 阳性对照组 | 1.44±0.03**## |
| 实例1组 | 1.21±0.01**## |
| 实例2组 | 1.23±0.05**## |
| 实例3组 | 1.28±0.03**## |
注：表2中，与正常对照组比较，*P<0.05,**P<0.01；与模型组比较，#P<0.05,##P<0.01。
3.粉雏菊组合物对淋巴细胞因子分泌的影响
如表3所示，与空白对照组相比，模型组IFN-γ、IL-6水平降低(P<0.05)，说明环磷酰胺可显著抑制小鼠的免疫调节功能。与模型组相比，阳性对照组和实例1、2、3组IFN-γ、IL-6水平均显著恢复 (P<0.05)。结果表明，粉雏菊组合物可以恢复环磷酰胺诱导的免疫抑制，通过增强细胞因子的分泌来增强免疫力。
表3.粉雏菊组合物对淋巴细胞因子分泌的影响
| 组别 | IFN-γ | IL-6 |
| 空白对照组 | 34.30±1.14 | 23.31±0.17 |
| 模型组 | 23.21±0.40** | 12.27±0.87** |
| 阳性对照组 | 30.39±0.40**## | 20.51±0.87**## |
| 实例1组 | 25.39±0.59**## | 14.44±0.49**## |
| 实例2组 | 26.48±0.62**## | 15.28±0.12**## |
| 实例3组 | 27.50±0.44**## | 17.18±0.78**## |
注：表3中，与正常对照组比较，*P<0.05,**P<0.01；与模型组比较，#P<0.05,##P<0.01。
Claims (4)
1.一种增强免疫力的粉雏菊组合物，其特征在于，按照重量份数配比，包括以下组分：粉雏菊20-50重量份、生姜5-30重量份、甘草5-25重量份。
2.根据权利要求1所述的粉雏菊组合物，其特征在于，所述组分进行优选：粉雏菊20-35重量份、生姜5-20重量份、甘草5-15重量份。
3.根据权利要求1-2任一项所述的一种具有增强免疫力的粉雏菊组合物的制备方法，其特征在于，将原料总重量10倍份的蒸馏水，浸泡半小时，然后煎煮2次，每次煎煮1.5小时，合并煎液，尽快过滤，除去滤渣，将滤液浓缩至适当体积，制得一种增强免疫力的粉雏菊组合物。
4.根据权利要求3所述的一种增强免疫力的粉雏菊组合物的制备方法，其特征在于，所述增强免疫力的粉雏菊组合物的剂型可以为煎剂口服液、颗粒剂或胶囊剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111156452.5A CN113975363A (zh) | 2021-09-30 | 2021-09-30 | 一种增强免疫力的粉雏菊组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111156452.5A CN113975363A (zh) | 2021-09-30 | 2021-09-30 | 一种增强免疫力的粉雏菊组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113975363A true CN113975363A (zh) | 2022-01-28 |
Family
ID=79737309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111156452.5A Pending CN113975363A (zh) | 2021-09-30 | 2021-09-30 | 一种增强免疫力的粉雏菊组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113975363A (zh) |
-
2021
- 2021-09-30 CN CN202111156452.5A patent/CN113975363A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA11396A (en) | Herbal extract composition and method with immune-boosting capability. | |
| CN102058817B (zh) | 一种治疗肝病的藏药制剂 | |
| CN104706707A (zh) | 一种抗病毒增强免疫人参保健品 | |
| CN104857435B (zh) | 一种具有抗肿瘤活性的中药复方组合物及其制备方法和应用 | |
| GB2581592A (en) | Preparation procedure for panax notoginseng medicinal liquor for oral administration for treating rheumatic ostalgia | |
| KR102151019B1 (ko) | 기억력, 학습력 향상 및 스트레스 완화용 총명탕 조성물 | |
| CN104857436B (zh) | 具有抗肝癌活性的中药复方组合物及其制备方法和应用 | |
| CN113975363A (zh) | 一种增强免疫力的粉雏菊组合物 | |
| CN106310017B (zh) | 一种治疗弥漫性肺间质纤维化肺肾气虚证的中药颗粒 | |
| CN108498568A (zh) | 用羊胎盘或胚胎治疗自体免疫性与免疫相关性疾病的中成药、医用食品及制备方法 | |
| CN104840727B (zh) | 具有抗食道癌活性的中药组合物及其制备方法和应用 | |
| CN1101559A (zh) | 一种中药抗癌口服液及其制备方法 | |
| CN115006466B (zh) | 一种治疗湿热兼阳虚型湿疹的中药制剂及其制备方法 | |
| CN116036174B (zh) | 一种治疗肺结节的药物及其制备方法 | |
| CN109260297B (zh) | 一种用于治疗痔疮的中药组合物及其制备方法 | |
| CN1209158C (zh) | 一种治疗小儿病毒性肺炎的清肺口服液制剂及其制备方法 | |
| CN102641403B (zh) | 一种治疗和/或预防艾滋病的中药组合物及其制备方法 | |
| CN110025685B (zh) | 一种含有蜂胶的组合物液体制剂 | |
| CN100515452C (zh) | 五味消毒饮现代中药口服制剂 | |
| CN106727926B (zh) | 抗肝纤维化及治疗肝硬化的药物及制备方法 | |
| RU2423996C1 (ru) | Способ лечения желудочно-кишечных болезней телят фитопрепаратом | |
| CN1255177C (zh) | 清热解毒制剂及其制备方法 | |
| Bayat-Movahed et al. | Effects of Qigong exercises on 3 different parameters of human saliva | |
| CN104825784B (zh) | 一种具有抗胃癌活性的中药组合物及其制备方法和应用 | |
| CN1245204C (zh) | 一种治疗急性咽炎的药物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |